Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-803 + Chemoimmunotherapy in Relapsed/Refractory Neuroblastoma
NCT07085338Phase 2Recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Nov 2025
- Primary completion
- Feb 2028
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of nogapendekin alfa inbakicept in neuroblastoma, sponsored by St. Jude Children's Research Hospital. Started Nov 2025; status: recruiting.
02
Drugs
nogapendekin alfa inbakicept
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT07085338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07085338.